250
Participants
Start Date
February 28, 2007
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
pegylated interferon alpha and plus ribavirin
pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
pegylated interferon alpha and plus ribavirin
pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
pegylated interferon alpha and plus ribavirin
pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
Kaohsiung Medical University Hospital, Kaohsiung City
Kaohsiung Medical University Chung-Ho Memorial Hospital
OTHER